Ascendis Pharma A-S
Yahoo Finance • 4 days ago
European Equities Traded in the US as American Depositary Receipts Decline Sharply in Wednesday Trading
European equities traded in the US as American depositary receipts were tracking lower late Wednesda PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story
Yahoo Finance • 12 days ago
Big Pharma Has a Case of Merger Mania
In this episode of Motley Fool Hidden Gems Investing, Motley Fool contributors Tyler Crowe, Matt Frankel, and Lou Whiteman take a dive into what’s driving the merger-and-acquisition frenzy, including: Big pharma is using big wallets for M... Full story
Yahoo Finance • 16 days ago
Ascendis Pharma added to Russell 3000, Russell 1000 and other U.S. indexes
Ascendis Pharma (ASND [https://seekingalpha.com/symbol/ASND]) said [https://seekingalpha.com/pr/20565715-ascendis-joins-multiple-russell-u-s-indexes-including-the-russell-3000-russell-1000-russell] on Friday it was added to the Russell 300... Full story
Yahoo Finance • 16 days ago
Ascendis Joins Multiple Russell U.S. Indexes, Including the Russell 3000®, Russell 1000®, Russell 2500® and Russell Midcap®
COPENHAGEN, Denmark, June 26, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the Company has been added to the broad-market Russell 3000® Index, the large-cap Russell 1000® Index, the small-to-mid-cap Ru... Full story
Yahoo Finance • 29 days ago
Phase 3 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism
Multi-organ system and quality-of-life benefits sustained through three and a half years 86% response rate for the multi-component endpoint 89% of patients completed the three-and-a-half-year trial COPENHAGEN, Denmark, June 13, 2026 (GL... Full story
Yahoo Finance • 30 days ago
European Equities Traded in the US as American Depositary Receipts Increase in Friday Trading; Rise for Week
European equities traded in the US as American depositary receipts were trending higher late Friday PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium... Full story
Yahoo Finance • last month
Ascendis Pharma Says TransCon PTH Shows Sustained Efficacy at 5 Years
Ascendis Pharma (ASND) said late Thursday that five-year data from its Phase 2 PaTH Forward trial sh PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story
Yahoo Finance • last month
5-Year Phase 2 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH in Adults with Hypoparathyroidism
– Multi-organ system and quality-of-life benefits sustained through five years of treatment – 82% response rate for the multi-component endpoint – 95% of patients completed five years of treatment COPENHAGEN, Denmark, June 11, 2026 (G... Full story
Yahoo Finance • last month
Ascendis Pharma (ASND):10 Most Profitable Growth Stocks to Buy
Ascendis Pharma (NASDAQ:ASND) is one of the most profitable growth stocks to buy. On May 7, Ascendis Pharma reported strong financial results for Q1 2026, reaching a total revenue of €247 million. This growth was primarily driven by YORVIP... Full story
Yahoo Finance • last month
Ascendis to Showcase Advances in Treatment of Rare Endocrine Diseases at ENDO 2026
COPENHAGEN, Denmark, June 08, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the latest data from its Endocrinology Rare Disease programs in hypoparathyroidism, achondroplasia, and pediatric growth hormo... Full story
Yahoo Finance • last month
Assessing Ascendis Pharma (ASND) Valuation After Recent Share Price Weakness
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Event context and recent price moves Ascendis Pharma (NasdaqGS:ASND) has recently drawn investor attention after the... Full story
Yahoo Finance • 2 months ago
JPMorgan sees biotech sector at inflection point, resumes coverage on 14 Firms
Investing.com -- JPMorgan has reinstated ratings and price targets on 14 large-cap biotechnology companies, describing the sector as being at a critical “inflection point” as pipeline successes increasingly translate into profitable commer... Full story
Yahoo Finance • 2 months ago
StubHub, Jazz Pharmaceuticals upgraded: Wall Street's top analyst calls
The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: Guggenheim upgraded StubHub (STUB) to... Full story
Yahoo Finance • 2 months ago
Liberty All-Star® Growth Fund, Inc. April 2026 Monthly Update
BOSTON, May 15, 2026--(BUSINESS WIRE)--Below is the April 2026 Monthly Update for the Liberty All-Star Growth Fund, Inc. (NYSE: ASG). Liberty All-Star Growth Fund, Inc. Ticker: ASG Monthly Update, April 2026 Investment Approach: Fund St... Full story
Yahoo Finance • 2 months ago
Energy Fund Yielding 7% and Up 14% in a Year Still Wasn’t Enough to Stop This $3 Million Exit
Matisse Capital fully exited its position in Kayne Anderson Energy Infrastructure Fund(NYSE:KYN), selling 222,839 shares for an estimated $2.99 million based on quarterly average pricing, the firm’s May 8, 2026, SEC filing shows. What hap... Full story
Yahoo Finance • 2 months ago
Ascendis Pharma A/S Q1 Earnings Call Highlights
Ascendis Pharma A/S logo Key Points FDA approval of Ascendis's third TransCon product, YUVIWEL, was secured and the therapy launched in early April, already prescribed for more than 60 children across 35+ providers; management plans to p... Full story
Yahoo Finance • 2 months ago
New 2-Year Data from Pivotal ApproaCH Trial of TransCon® CNP (Navepegritide) Show Pronounced Gains in Growth Outcomes in Children with Achondroplasia Aged ≥5 Years
COPENHAGEN, Denmark, May 06, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced new data from a subgroup analysis showing that children with achondroplasia ≥5 years of age at enrollment treated with once-weekly T... Full story
Yahoo Finance • 3 months ago
Ascendis Pharma A/S (ASND): Billionaire Joe Edelman Is Bullish on This Stock
We just covered the Billionaire Joe Edelman’s 10 Stock Picks with Huge Upside Potential and Ascendis Pharma A/S (NASDAQ:ASND) ranks 9th on this list. The primary catalyst for hedge fund interest in Ascendis Pharma A/S (NASDAQ:ASND) stock... Full story
Yahoo Finance • 3 months ago
European Equities Traded in the US as American Depositary Receipts Edge Higher in Wednesday Trading
European equities traded in the US as American depositary receipts were higher late Wednesday mornin PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story
Yahoo Finance • 3 months ago
Ascendis Announces Redemption of All $575 Million of Outstanding 2.25% Convertible Senior Notes Due 2028
COPENHAGEN, Denmark, April 21, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that it has called all $575.0 million aggregate principal amount of its outstanding 2.25% Convertible Senior Notes due 2028 (the “... Full story